Revolution in the diagnosis and management of hepatitis C virus infection in current era

Abstract

Chronic hepatitis C virus (HCV) infection is a major global public health problem, particularly in developing part of the world. Significant advances have been made in the early diagnosis and treatment of the disease. Its management has been particularly revolutionized during the past two decades. In this review, we summarize the major advances in the diagnostic and management armamentarium for chronic HCV infection. The focus of the present review is on the newer directly acting anti-viral agents, which have revolutionized the management of chronic HCV infection. Management of uncomplicated chronic HCV infection and of specific complications and special at-risk populations of patients will be covered in detail. Despite the advent and approval of highly effective and well tolerable oral agents, still many challenges remain, particularly the affordability, the equitable distribution and access to later drugs. The World Health Organization aims to eliminate viral hepatitis including HCV by 2030 since its poses a major public health threat. There is an urgent need to ensure uniform and early access to diagnostic and therapeutic facilities throughout the world if the later goal has to be realized.

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir

“…Combination therapy of interferon and ribavirin has been used in Pakistan for a long time. For this reason, much research is being done on this topic [11,12]. In recent years, direct-acting antivirals have been just introduced in Pakistan.…”

Genomic divergence of Hepatitis C virus towards common prescribed interferon regimens on sustained virologic response (SVR) ‎

“…The Hepatitis C virus (HCV) is a significant issue of public health that impacts 170 million people globally. It represents the most prevalent cause of chronic hepatitis, cirrhosis, and liver cancer worldwide, as well as the principal reason for liver transplants [1,2], and some research revealed that HCV-related mortality (death from liver failure or hepatocellular carcinoma) will keep going up throughout the next couple of decades [3]. Hepatitis C virus (HCV) infection is getting more widespread all over the world.…”